Clinical Trial Detail

NCT ID NCT04310007
Title Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lung non-squamous non-small cell carcinoma

lung non-small cell carcinoma

Therapies

Nab-paclitaxel

Gemcitabine

Cabozantinib + Nivolumab

Cabozantinib

Docetaxel

Paclitaxel

Docetaxel + Ramucirumab

Age Groups: adult senior

Additional content available in CKB BOOST